Project Grant R41HD110310
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $499,932 to Safebvm Corp., a small disadvantaged business located in Boston, MA, to integrate the company's SOTAIR device with capnography monitoring to standardize manual ventilation techniques and improve patient outcomes. The SOTAIR device is designed to prevent complications associated with improper manual ventilation, which can lead to costly complications...
- The National Science Foundation (NSF) awarded Compact Medical Inc., a for-profit medical device manufacturer, a $999,931 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The funding supports the development and testing of a novel, adjustable bag-valve-mask (BVM) resuscitator device that allows emergency providers to deliver customized air volumes and pressures based on patient body size. This advanced resuscitator aims to address issues with...
- This Project Grant award of $866,579, awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) on January 20, 2025, supports a study to evaluate the effectiveness of the OPTI-VENT bundle in improving survival to discharge with favorable neurological outcomes for children receiving at least 1 minute of cardiopulmonary resuscitation (CPR) during in-hospital cardiac arrest. The OPTI-VENT bundle consists of provider education and point-of-care CPR...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $816,119 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oregon Health & Science University (OHSU). The overall objective of this 4-year project is to conduct an in-depth analysis of pediatric prehospital emergency ventilation and identify the ventilation strategy associated with the best patient outcomes. The project will leverage data collected through the NHLBI-funded PEDI-PART trial, which...
- This Project Grant from the National Science Foundation's Division of Industrial Innovation, under the Engineering program (CFDA 47.041), provides $256,000 to Colabs, Inc. to develop an automated airway and ventilator system that eliminates human operator variability during cardiopulmonary resuscitation (CPR). The system aims to reliably place an airway tube for ventilation, synchronize air delivery with chest compressions, and enable cardiac defibrillation at lower voltages through an electrode...
- The National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $305,218 Project Grant to Respair, Inc. for the development of ASSURANCEET, a novel endotracheal tube with a micro-baffle sealing mechanism to protect pediatric patients from airway trauma and collapse. The goal of the project is to assess the feasibility and safety of the ASSURANCEET device for use in pediatric airways, as the current endotracheal tube designs...
- Compact Medical Inc. received a $255,925 Small Business Innovation Research Phase I Project Grant from the National Science Foundation to develop a novel respiratory bag-valve-mask resuscitator. The grant was awarded on August 15, 2021 under the NSF's Engineering program (CFDA #47.041) and will support product development activities through February 28, 2022. The Engineering program seeks to foster innovation in engineering research and education to improve quality of life and economic strength....
- This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- The National Heart, Lung, and Blood Institute (NHLBI), under the federal Cardiovascular Diseases Research program (CFDA 93.837), awarded a $306,643 project grant to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed to efficiently accommodate the low flow rates needed for pediatric and neonatal patients. The project aims to design, develop, and test a low-flow ECMO pump capable of operating at flow rates from 0.05 to 0.5 L/min, which is an order of...
THE BUTTERFLY BVM, A NOVEL RESUSCITATOR TO PREVENT HYPERVENTILATION IN PEDIATRIC RESUSCITATION - PROJECT SUMMARY BAG-VALVE-MASK (BVM) RESUSCITATORS ARE DIFFICULT TO USE CORRECTLY AND ARE COMMONLY MISUSED, EVEN BY TRAINED MEDICAL PERSONNEL. MISUSE CAN RESULT IN SERIOUS INJURY AND DEATH DUE TO VOLUTRAUMA OR BAROTRAUMA, AND THIS IS PARTICULARLY CONCERNING WHEN RESUSCITATING PEDIATRIC PATIENTS, IN WHOM THERE IS AN EXTREME RANGE IN LUNG VOLUME. TRADITIONAL BVMS PROVIDE NO ADEQUATE MEANS OF RESTRICTING THE VOLUME OF AIR DELIVERED WHEN THE BAG IS SQUEEZED, SO MEDICAL PERSONNEL RELY ON THEIR ABILITY TO MONITOR CHEST RISE TO DETERMINE WHETHER THEY ARE DELIVERING AN APPROPRIATE VOLUME. CHEST RISE CAN BE ESPECIALLY DIFFICULT TO MONITOR IN PEDIATRIC PATIENTS UNDER EMERGENCY CONDITIONS, WHEN SIMULTANEOUS MONITORING OF PEAK INSPIRATORY PRESSURE (BY OBSERVING A MANOMETER) AND OTHER PATIENT PARAMETERS IS REQUIRED. SIMILARLY, THE RATE AT WHICH BREATHS ARE DELIVERED IS NOT REGULATED BY TRADITIONAL BVMS, AND MEDICAL PERSONNEL OFTEN EXCEED SAFE RATES. COMPACT MEDICAL, INC. IS DEVELOPING A SAFER, EASY-TO- USE DEVICE, THE BUTTERFLY BVM RESUSCITATOR, THAT RESTRICTS THE VENTILATION VOLUME, RATE, AND PRESSURE TO SAFE LEVELS THAT CAN BE QUICKLY SET ACCORDING TO THE PATIENT. THE DEVICE'S "CONCERTINA" DESIGN ALLOWS EASIER COMPRESSION WITH ONE HAND, LEAVING THE OTHER HAND FREE TO MAINTAIN THE SEAL BETWEEN THE MASK AND THE PATIENT'S AIRWAY. IN A STUDY WITH END-USERS AT INDIANA UNIVERSITY SIMULATION CENTER, A FULLY FUNCTIONAL PROTOTYPE WILL BE TESTED TO VALIDATE ITS SAFETY FEATURES VERSUS A TRADITIONAL BVM FOR PEDIATRIC APPLICATIONS AND TO GATHER USER FEEDBACK. AIM 1 IS DESIGNED TO TEST THE ABILITY OF THE BUTTERFLY BVM TO PROMOTE GUIDELINE-CONSISTENT PATIENT CARE BY USERS WHO HAVE HAD A MINIMAL INTRODUCTION TO THE DEVICE. SIXTY PARTICIPANTS TRAINED IN PEDIATRIC EMERGENCY RESUSCITATION (PHYSICIANS, RESPIRATORY THERAPISTS, AND EMERGENCY MEDICAL TECHNICIANS; 20 PER GROUP) WILL RECEIVE A MINIMAL INTRODUCTION TO THE BUTTERFLY BVM AND PERFORM A SERIES OF RESUSCITATION TASKS USING THE BUTTERFLY BVM AND A TRADITIONAL BVM UNDER CONDITIONS DESIGNED TO REPLICATE HIGH-STRESS PEDIATRIC EMERGENCY RESUSCITATION SCENARIOS (MOCK CODES). THE TASKS WILL BE PERFORMED ON A MANNEQUIN SYSTEM THAT COLLECTS AIR VOLUME, BREATH RATE, AND PRESSURE DATA. AIM 2 IS DESIGNED TO DETERMINE WHETHER THE USERS CAN LEARN WITH A BRIEF INTRODUCTION HOW TO MANIPULATE THE SETTINGS OF THE DEVICE TO FIT PREDETERMINED CLINICAL SCENARIOS. FOLLOWING THE MOCK CODES IN AIM 1, THE PARTICIPANTS WILL BE SHOWN A BRIEF INSTRUCTIONAL VIDEO FULLY INTRODUCING THE BUTTERFLY BVM AND ITS OPERATION AND GIVEN 5 MINUTES TO FAMILIARIZE THEMSELVES WITH THE DEVICE BEFORE ENGAGING IN ANOTHER SERIES OF MOCK CODES THAT REQUIRE THE BUTTERFLY BVM'S SETTINGS TO BE MODIFIED. THE PARTICIPANTS' ABILITIES TO CORRECTLY MANIPULATE THE BUTTERFLY BVM'S SETTINGS WILL BE RECORDED, AND A QUESTIONNAIRE WILL BE ADMINISTERED TO GATHER USER PERCEPTIONS AND FEEDBACK. PROJECT MILESTONES INCLUDE CONSISTENT RESTRICTION OF MINUTE VENTILATION AND PRESSURES TO AHA-RECOMMENDED LEVELS, SIGNIFICANT REDUCTIONS IN STANDARD DEVIATIONS FOR MINUTE VENTILATION AND PEAK PRESSURE VS. A TRADITIONAL BVM, AND 75% USER PREFERENCE FOR AND CORRECT USE OF THE BUTTERFLY BVM FOR PEDIATRIC RESUSCITATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/11/24 | ||
| Not listed | $0 | 11/4/22 | ||
| Not listed | $0 | 11/4/22 | ||
| Not listed | $300.0k | 9/20/22 | ||
| Not listed | $300.0k | 9/20/22 |